119 related articles for article (PubMed ID: 38482602)
1. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.
Ahlberg M; Garmo H; Stattin P; Gedeborg R; Edlund C; Holmberg L; Bill-Axelson A
Scand J Urol; 2024 Mar; 59():63-69. PubMed ID: 38482602
[TBL] [Abstract][Full Text] [Related]
2. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
[TBL] [Abstract][Full Text] [Related]
3. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
Gallagher KM; Christopher E; Cameron AJ; Little S; Innes A; Davis G; Keanie J; Bollina P; McNeill A
BJU Int; 2019 Mar; 123(3):429-438. PubMed ID: 30113755
[TBL] [Abstract][Full Text] [Related]
4. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
5. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
6. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
7. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
8. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
9. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
10. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
[TBL] [Abstract][Full Text] [Related]
11. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
12. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
13. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
15. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
16. Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes.
Ahlberg MS; Garmo H; Holmberg L; Bill-Axelson A
Eur Urol Open Sci; 2023 Jun; 52():166-173. PubMed ID: 37284040
[TBL] [Abstract][Full Text] [Related]
17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
18. Five-year nationwide follow-up study of active surveillance for prostate cancer.
Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
[TBL] [Abstract][Full Text] [Related]
19. Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer.
Björnebo L; Olsson H; Nordström T; Jäderling F; Grönberg H; Eklund M; Lantz A
World J Urol; 2021 Jun; 39(6):1797-1804. PubMed ID: 32734463
[TBL] [Abstract][Full Text] [Related]
20. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
